Longboard Pharmaceuticals Says Ended Q2 2023 With $63M In Cash
Portfolio Pulse from Benzinga Newsdesk
Longboard Pharmaceuticals has announced that it ended the second quarter of 2023 with $63 million in cash.

August 04, 2023 | 2:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longboard Pharmaceuticals ended Q2 2023 with $63 million in cash, indicating a strong financial position.
The announcement of ending the quarter with a substantial amount of cash indicates a strong financial position for Longboard Pharmaceuticals. This could potentially attract investors, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100